From genomic data analysis to drug development: a new generation of trials using molecular marker assessment in...

Area of Science:

• Oncology
• Genomics
• Translational Medicine

Background:

• The classification of breast cancer into molecular subtypes has transformed clinical trials and drug development.
• Despite advances in molecular screening, identifying actionable targets remains a challenge, necessitating innovative trial designs.

Purpose of the Study:

• To review the evolution of sequencing technologies and their impact on identifying druggable targets in breast cancer.
• To discuss novel clinical trial designs for hormone receptor-positive breast cancer, optimizing targeted therapy development.
• To address the challenges of treatment adaptation and resistance mechanisms in personalized breast cancer therapy.

Main Methods:

• Review of current sequencing technologies and their application in molecular screening for breast cancer.
• Analysis of the impact of molecular screening on drug development strategies.
• Examination of successful clinical trial designs incorporating targeted therapies for hormone receptor-positive breast cancer.

Main Results:

• Molecular screening identifies a wide spectrum of mutations, but the number of clinically actionable targets is limited.
• Novel trial designs are emerging to address the complexities of targeted therapy development and patient stratification.
• Optimizing treatment combinations requires careful consideration of mutation profiles and potential resistance mechanisms.

Conclusions:

• Advancements in sequencing technologies have improved molecular profiling in breast cancer, yet translating findings into effective therapies requires refined clinical trial strategies.
• Developing adaptive combination therapies for hormone receptor-positive breast cancer necessitates a balance between comprehensive mutation analysis and practical therapeutic constraints.
• Future efforts should focus on innovative trial designs that facilitate the development of targeted therapies and overcome treatment resistance, ultimately improving patient outcomes.